Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr Lotan on Ongoing Research With Novel Agents in BCG-Unresponsive NMIBC

November 5th 2024

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

Dr Braun on Advancements in Biomarker Development in RCC

October 31st 2024

David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.

Dr Badami on a Case Study Illustrating Key Decisions for First-Line Metastatic RCC

October 31st 2024

Ami Umesh Badami, MD, discusses a case study illustrating key decisions in the treatment of metastatic renal cell carcinoma.

Dr Sharma on the Clinical Utility of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

October 31st 2024

Janaki Neela Sharma, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced/metastatic bladder cancer.

Dr Tan on the Role of Nivolumab/Ipilimumab in Favorable-Risk Advanced RCC

October 29th 2024

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC

October 29th 2024

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

Dr Lotan on Factors Informing Treatment Selection in BCG-Unresponsive NMIBC

October 28th 2024

Yair Lotan, MD, discusses factors informing treatment selection for patients with BCG-unresponsive non-muscle invasive bladder cancer.

The OncFive: Top Oncology Articles for the Week of 10/20

October 26th 2024

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer

October 25th 2024

TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.

Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm

October 24th 2024

Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.

Dr Friedlander on the Design and Methods of the Duravelo-2 Trial in Urothelial Cancer

October 23rd 2024

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

The OncFive: Top Oncology News and Trends for the Week of 10/13

October 19th 2024

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Gilead to Withdraw US Indication for Sacituzumab Govitecan in Metastatic Urothelial Cancer

October 18th 2024

Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.

Bel-Sar Elicits Complete Responses in NMIBC

October 17th 2024

Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.

Dr Friedlander on Emerging Agents of Interest in Urothelial Cancer

October 17th 2024

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

Dr Lee on the Significance of the Tumor-Agnostic Approval of T-DXd for HER2+ Urothelial Cancer

October 16th 2024

John K. Lee, MD, PhD, discusses the significance of the tumor-agnostic approval of T-DXd specifically for patients with HER2-positive urothelial cancer.

ADCs Usher in a Complex New Era of Disease and Toxicity Management in Bladder Cancer

October 15th 2024

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

Dr Sonpavde on an Exploratory Analysis of CheckMate 901 in Metastatic Urothelial Cancer

October 14th 2024

Guru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.

Cisplatin’s Prevalence in Bladder Cancer Falters With the Introduction of Enfortumab Vedotin

October 11th 2024

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.